Cyprotex
Tim Potter is a seasoned professional in business development and pharmaceutical sciences, currently serving as Vice President of Business Development at Cyprotex since October 2010. Potter leads the European business development team and focuses on expanding operations in Europe and the Asia-Pacific regions, with expertise in drug metabolism and pharmacokinetics and in vitro toxicology. Previous roles at Cyprotex include Senior Director, Director, and Head of Project Management, all emphasizing revenue generation and client management. Prior experience at AstraZeneca as a Senior Research Scientist involved contributions to lead optimization projects and assay development. Tim Potter holds a PhD in Chemistry and an MChem in Chemistry, both from The University of Sheffield.
This person is not in any offices
Cyprotex
Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development. * High-throughput ADME screening * Customised ADME assays * In silico ADME predictive modeling * In vitro toxicology